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ABSTRACT
Yellow fever is one of the most important mosquito-borne diseases, which still affects a 
significant number of people every year, mainly in tropical countries. Mortality can be high, 
even with intensive treatment due to multiple organ failure, including acute kidney injury 
(AKI). This disease can also be a burden on the health care system in developing countries, 
without mentioning the number of lives that could be spared with an early diagnosis and 
adequate monitoring and treatment. The pathophysiology of yellow fever-induced acute 
kidney injury (AKI) is still to be completely understood, and the best clinical approach has 
not yet been determined. This manuscript presents the most recent scientific evidence of 
kidney involvement in yellow fever, since AKI plays an important role in the mortality rate. 
Recent outbreaks have occurred in Brazil and further studies are required to provide a better 
clinical control for patients with yellow fever. 
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INTRODUCTION
The genus Flavivirus, of the Flaviviridade family, is composed of some of the 
most pathogenic human viruses (Arboviruses), including Dengue virus (DENV), 
Yellow fever virus (YFV), Zika virus (ZIKV) and West Nile virus (WNV), among 
others1-4. These are mosquito-borne diseases transmitted by the same hematophagous 
arthropod vectors, and their main hosts are vertebrate animals, with primates, humans 
and non-humans, as hosts1,3,5. 
Yellow fever virus, the etiological agent of YF, belongs to the Flaviviridae 
family, genus Flavivirus, which are enveloped positive-sense single-stranded 
RNA viruses6-8. The production of a single polyprotein of the YFV occurs after the 
virus infects a host cell, thus beginning the translation of the viral genome. The thi 
protein is cleaved by the YFV proteases of the host, producing viral proteins that 
are essential for the virus genome replication and virion production7,9. A meticulous 
study of the yellow fever virus genome is essential to establish genetic differences 
between virus strains, helping the development of new treatments7,9.
In Brazil, there have been no reports on an urban cycle of the mosquito since 
1942. However, the enzootic cycle (sylvatic yellow fever cycle involving non-human 
primates) occurs in the Amazon basin region8,10.
In the last two years, there has been a recrudescence of yellow fever (YF) in 
some countries in Africa and South America11, highlighting the need for effective 
tools and protocols against this arboviral disease, enhancing medical practices 
and public health policies in this field. As YF is not easily diagnosed, an adequate 
Lopes et al.
Rev Inst Med Trop São Paulo. 2019;61:e35Page 2 of 11
diagnosis constitutes the first line of defense. Laboratory 
confirmation of suspected cases of YF must be promptly 
performed, as it is imperative for the effective control of 
outbreaks and the prevention of disease dissemination12.
The severe viscerotropic disease caused by YFV has 
a high mortality rate, ranging from 25% to 50%13-15. The 
yellow fever virus is one of the most critical arboviruses. 
Annually, this virus is globally responsible for many new 
cases of disease (approximately 200,000) and some of them 
are fatal (30,000 deaths)2,14,16,17.
Yellow fever causes a pan-systemic febrile illness, with 
hepatic, renal and myocardial lesions. In more severe cases, 
internal hemorrhage, kidney failure, shock, coma or even 
death can occur11. In the most severe cases, the mortality rate 
is between 20-50%15. Genetic factors seem to offer some 
protection, but according to Monath and Vasconcelos11, 
more studies are required to prove this hypothesis. 
Currently, specific antiviral treatment is not available for 
yellow fever (YF). Prevention and vaccination are the 
key control-factors in high-risk areas18. These areas are 
composed mainly of tropical forests in which the sylvatic 
cycle was first described in the 1930s and early 1940s19,20.
A huge YF epidemic occurred in Rio de Janeiro/ Brazil 
between 1928 and 192921. However, since 1942, no other 
cases have been reported in the major Brazilian cities. 
At the beginning of the 21th century, new cases of yellow 
fever outside the rainforest environment have become a 
matter of concern for the Brazilian health authorities due to 
the expansion of the viral circulation area and the possibility 
of travelers carrying the virus to other countries21.
Some outbreaks and YF cases in non-epidemic areas 
have been reported. Since 2015, Brazil has faced significant 
sylvatic yellow fever outbreaks in the four States of the 
Southeast region, mainly due the insufficient vaccination 
coverage, since these States are not YF epidemic areas22,23. 
In addition, by the end of the 20th century, the YF virus has 
spread to the Atlantic forest regions (Southeast and South 
of Brazil) increasing the number of infected primates and 
humans24.
YF urban outbreaks have been observed in Africa, as 
well. They occurred in December 2015, in Angola, and 
afterwards in the Democratic Republic of Congo in which 
persisted until January 2017, according to The World Health 
Organization (WHO)25-27. This 2015 outbreak in Angola was 
considered the most significant and widespread outbreak 
in Africa in more than 20 years20. Furthermore, in 2016, an 
unconnected yellow fever outbreak took place in Uganda 
(Africa), and some occasional YF cases were reported in 
Chad, Ghana, Republic of Congo and Guinea later on, and, 
more recently, Nigeria has been facing an active yellow 
fever outbreak25-27.
Historical aspects and epidemiology
There is convincing evidence to the hypothesis that 
sylvatic YFV was introduced in the New World about four 
centuries ago, from West Africa to South America and the 
Caribbean during the slave trafficking period17. It seems that 
the YFV could only have been introduced through people 
presenting with viremia or by an infected vector (A. aegypti), 
as the yellow fever was very unusual on sailing ships3,28,29.
Since the 1950s, the transmission of YFV in the 
Americas occurred mainly through a sylvatic cycle 
involving primates and mosquitoes (Haemagogus and 
Sabethes genera). YFV is extremely pathogenic to primates 
and non-immune people24,29. The epizootic cycle, which is 
responsible for sylvatic cycle epidemics, appears in regular 
periods in some specific regions. Besides, the epizootic 
cycle may overlap sporadic yellow fever outbreaks in non-
immunized populations that live in or close to the forest24. 
Globally, Fernandes et al.30 point out that the first 
probable exposure to YFV infection occurred 500 years 
ago, in 1585, in West Africa. Moreover, the first epidemic 
event was recorded in the 17th century, when it was 
already considered a public health threat. Moreover, the 
dissemination of the YFV in Brazil was associated to 
trans-oceanic migrations, because these migrations brought 
the virus to Brazil and it has gradually spread out to the 
Northeast and Midwest regions30. 
Locations such as Africa and the Americas are considered 
areas of YFV epidemic threat, due to their historical 
epidemic records even within the US31. Tretyakova et al.31 
mentioned that the World Health Organization (WHO) has 
estimated that every year, 200,000 new cases of YF and 
30,000 deaths will occur worldwide, even though the YF 
current geographic distribution includes mainly African and 
South American tropical areas. 
Yellow fever sporadically disappears during the winter 
period18. According to the Brazilian Ministry of Health and 
the WHO32,33, yellow fever is a seasonal disease that mostly 
occurs during the summer, with December and January 
being the hottest months in the Southern Hemisphere, when 
there is a higher number of confirmed cases, as shown in 
Figure 1. 
Moreover, the Brazilian Ministry of Health published in 
February 2018 that 1,080 yellow fever cases were notified 
between July 2017 and January 2018, of which 213 were 
confirmed and 81 resulted in death32, as shown in Table 1.
The Brazilian Amazon basin is an epidemic area for 
yellow fever. However, sporadic outbreaks may occur 
outside this region, as shown in 2016, when thousands of 
yellow fever cases in humans were reported (more than 
1,900) in Southeastern Brazil10.
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According to the revised 2010 yellow fever map, Brazil 
is one of the 11 South American countries within the YF 
endemic areas, and it is one of the seven countries where 
vaccination is required19. 
Fernandes et al.30 briefly explained how these massive 
outbreaks spread to areas outside the forest borders, by 
providing suitable environment for mosquitoes propagation 
in large Brazilian cities. If the YFV is circulating in 
the forest, primates can be infected, providing a new 
endemic area for sylvatic yellow fever. Therefore, the 
YFV moves forward through the forest areas, reaching 
cities that had been previously considered without risk of 
transmission30. 
Because South America (particularly Brazil, Argentina, 
Paraguay, Bolivia, and Peru) and African regions have 
notified YFV circulation34, and the displacement of 
asymptomatic patients infected with yellow fever virus has 
implications for the global dissemination of yellow fever, 
it is imperative that travelers are vaccinated, due the high 
risk of yellow fever transmission23,25,33.
Figure 1 - Distribution of confirmed cases of yellow fever 
in Brazil in the seasonal monitoring period. Adapted from 
Ministério da Saúde32.
Table 1 - Distribution of reported yellow fever cases in Brazil, from July the 1st 2017 to January the 30th 2018.
Region Brazilian states (probable 
site of infection) Notified Discarded
Under 
investigation Confirmed Death
North
Amapa 2 2 0 - -
Amazonas 4 2 2 - -
Para 23 13 10 - -
Rondonia 5 5 0 - -
Roraima 2 2 0 - -
Tocantins 9 6 3 - -
Northeast
Bahia 15 7 8 - -
Ceara 1 1 0 - -
Maranhao 1 1 0 - -
Pernambuco 1 0 1 - -
Piaui 3 1 2 - -
Rio Grande do Norte 1 1 0 - -
Midwest
Distrito Federal 27 18 8 1 1
Goias 26 16 10 - -
Mato Grosso 1 0 1 - -
Mato Grosso do Sul 5 3 2 - -
Southeast
Espirito Santo 64 44 2 - -
Minas Gerais 244 71 96 77 30
Rio de Janeiro 34 3 4 27 7
Sao Paulo 573 216 249 108 43
South
Parana 18 14 4 - -
Rio Grande do Sul 11 4 7 - -
Santa Catarina 8 2 6 - -
Total 1,080 432 435 213 81
Adapted from Ministério da Saúde32.
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 Yellow fever was initially described only in Africa, 
and then the sailing ships carrying slaves accidentally 
transported mosquitoes and infected people to the South 
and Central Americas, where mosquitoes adapted to those 
regions due to climate similarities and expanded their 
natural habitat. Currently, the areas listed below, adapted 
from the WHO25,33,34 reports, show the yellow fever 
geographic distribution worldwide (Figure 2). 
Pathogenesis and clinical manifestations
After the YFV-infected female mosquito bites, the 
virus infects dendritic cells within subcutaneous tissues 
and travels to the lymph nodes, where the virus replication 
occurs and the cellular immune response initiates. During 
this feeding process, approximately 1,000 to 100,000 viruses 
are inoculated into the host’s bloodstream, starting the 
replication stage (since virus cannot replicate outside a 
host). After this first RNA virus replication cycle, viruses 
are released into the bloodstream through the lymphatic 
channels (viremia) and they spread firstly to the regional 
lymph nodes. Then, they leave the lymph nodes and reach 
different organs, especially the liver, heart and kidneys.
In humans, the wild-type YFV infection is mainly 
viscerotropic and affects firstly the liver, before damaging 
other tissues, including the kidneys, spleen, lymph nodes 
and heart. After the incubation period, the first infection 
phase (1st stage) is characterized by a flu-like disease, during 
which fever is accompanied by chills, headache, nausea 
and myalgia. Then, a period of remission ensues, and most 
infected individuals recover. However, in the severe forms 
of YF, after a brief remission period (2nd stage) of no more 
than 48 h, some affected patients progress to the intoxication 
phase (3rd stage)27,33,35.
In this third stage (intoxication phase), the hemorrhagic 
and hepatic dysfunctions of this disease occur, and other 
multiple organ dysfunctions may also come along. The 
intoxication stage is severe and accompanied by symptoms 
characteristic of YF disease, including jaundice (which gave 
it the name of “yellow fever”), vomiting (black vomit or 
dark vomit, other ancient names of the disease) and other 
hemorrhagic manifestations such as vascular leakage8,27,36.
While the Haemagogus or Sabethes genera are the wild 
vectors, the Aedes aegypti mosquito, easily found in tropical 
cities, is the urban vector. A. aegypti is responsible for the 
dissemination of yellow fever in the urban environment. 
Therefore, the human-human transmission can occur when 
infected and non-infected humans are confined together, 
in the presence of a competent bridge represented by a 
domestic vector35. 
The spectrum of clinical disease in humans is broad, and 
the severity of yellow fever can cause symptoms ranging 
from inapparent infection to severe forms with internal 
hemorrhage and acute hepatic and renal dysfunction. In 
Figure 2 - Areas at risk of yellow fever transmission. Adapted from the World Health Organization34.
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humans, the YFV mainly affects the liver, promoting hepatic 
dysfunction and subsequently jaundice (yellowish skin). 
That was the reason the disease was named “yellow” fever, 
but other organs such as the heart, lymph nodes, spleen, 
kidneys and lungs are also viral replication sites35.
The initial symptoms are high fever, myalgia, low 
back pain, nausea and vomiting. Moreover, the evolution 
to the severe form of disease presenting with jaundice, 
hemorrhages, and, in some cases, multiple organ failure 
and shock may occur. Opportunistic diseases may also 
appear, and, according to Maciel et al.36, disseminated 
mycosis (severe infection in yellow fever patients) can 
mimic bacterial sepsis.
Diagnosis and diagnostic methods
One of the greatest challenges in yellow fever is the 
diagnosis of disease, because symptoms can be mistaken 
for other diseases such as respiratory, digestive or urinary 
infections37. Therefore, due the lack of symptoms specificity 
in the early stages of YF, the differential diagnosis is 
imperative, because yellow fever can be easily mistaken for 
other hemorrhagic diseases, such as leptospirosis, dengue 
fever, malaria and viral hepatitis2. Another important point is 
that YF shares the same vector and geographic areas of other 
tropical diseases, such as zika, dengue and chikungunya 
infections1,5. 
Additionally, the quick identification of zika, dengue 
and chikungunya viruses can indirectly help to control and 
prevent yellow fever, since the preventive measures to control 
the vector of these diseases will be the same1. Therefore, 
technological advances especially the molecular biology 
techniques, allow us to rapidly diagnose and differentiate 
diseases, and to be more assertive. To exemplify, there is a 
multiplex real-time PCR assay (RT-PCR) performed with 
primers and probes specifically designed to target and 
differentiate ZIKV, DENV, CHIKV and YFV1,5. Another 
method that can be used is a single real-time RT-PCR 
assay, but in this case RNA will be reverse transcribed and 
cDNA will be the target nucleic acid of these viruses, and 
this technique can be very helpful to manage outbreaks and 
control the spread of arboviral diseases1,2. 
The YF laboratory diagnosis is attained through 
the detection of YF antigens by measuring IgM (which 
is not always representative of a recent infection) and 
IgG-specific antibody, when the patient has viremia3,4,14,33,38. 
To confirm the presence of YFV, it is necessary to use 
immunohistochemical techniques to detect YF antigens 
in tissues or nucleic acids detection using amplification 
methods, such as Mac-ELISA/IFA, PCR, RT-PCT or other 
immunoassays such as flow cytometry, and microscopic 
analysis2-5,14,27,33,39,40. Laboratory investigation can also 
be performed by isolating the virus or its antigens in 
blood and tissue samples, or through the post-mortem 
histopathological analysis of tissues14,37, because the YF 
diagnosis is confirmed only through virus isolation (gold 
standard)39. More recent molecular techniques, such as 
the Point of Care (POC), can also be used to have more 
accurate laboratory diagnoses, using a portable equipment2. 
Nevertheless, it cannot be used in developing countries 
due to the lack of investment in health care resources and 
laboratory equipment40. POC has been used to detect ZIKV, 
CHIKV and DENV due its portability, specificity and 
sensitivity, using accessible samples such urine, saliva and 
tiny amounts of blood41. POC can be a great monitoring 
and diagnostic tool for yellow fever as well, because it can 
help to attain a faster diagnosis, being very specific, with 
a relatively low cost.
According to Zarei40, POC portability could benefit 
resource-limited regions even though there might be some 
barriers and challenges to overcome. However, the fact that 
it can be used in the field and not only in clinical settings 
is another reason that could help to attain a rapid diagnosis 
during outbreaks.
Other hemorrhagic diseases that constitute the 
differential diagnosis of yellow fever have been studied in 
search of bioactive molecules and toll-like receptors that can 
help to attain an accurate diagnosis41. This might indirectly 
help to diagnose YF when it is necessary to rule out other 
hemorrhagic infections that mimic it. 
Cytokines can also be elevated, such as interleukin 
6 (IL-6), interferon gamma-induced protein 10 (IP-10), 
monocyte chemoattractant protein 1 (MCP-1) and tissue 
necrosis factor alpha (TNF-α)14, but because they are 
immune-mediated and appear in inflammatory reactions, 
they are not specific for yellow fever. 
Attaining a correct diagnosis is essential, especially if 
there are concomitant infections, because yellow fever can 
quickly evolve to the severe forms of the disease or even 
death4,41.
Kidney injury in yellow fever
One of the targets for viral replication are kidney tissues. 
Some histological studies in non-human primates indicate 
that acute kidney tubular necrosis with protein cylinders 
and hemoglobin cylinders has some similarities with 
some classic histopathological findings of yellow fever in 
humans30. Maciel et al.36 described in details the kidney 
lesions observed in the autopsy of patients affected by the 
severe form of yellow fever virus infection, which was 
associated to disseminated mycoses. In addition, according 
Lopes et al.
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to the study by Maciel et al.36, interstitial nephritis was 
identified, associated with tubular necrosis and interlobular 
thrombosis in kidney vessels, as well as hemorrhage and 
ischemic necrosis of the adrenal gland.
The autopsy of another yellow fever patient showed 
that there was preservation of the parenchymal surface, 
showing only an irregular and hemorrhagic area in the 
upper pole of the left kidney, and a 1.5-cm cyst on the 
anterior face of the right kidney. The microscopic analysis 
revealed multiple interstitial nephritis foci, combined with 
fibrosis and tubular necrosis. Thrombosis and intraluminal 
inflammatory infiltrates were identified in the vessels. The 
suggestive zygomycotic finding was characterized as a 
typical fungal hypha (pauci-septated hyaline fungal hyphae 
with a lateral right-angle formation) in the intravascular and 
interstitial inflammatory foci. Moreover, multiple foci of 
hemorrhagic lesions and necrosis in the left adrenal gland 
were microscopically identified, while the right adrenal 
gland was normal36. 
Engelmann et al.42 described granular bilirubin 
cylinders in the dilated distal convoluted tubules and protein 
cylinders in the kidneys of animals that needed euthanasia. 
Surprisingly, the yellow fever virus antigen was not detected 
in kidney tissues, which indicates no association with the 
virus replication site.
As discussed by Engelmann et al.42, the yellow fever 
disease follows the same pattern in monkeys as described in 
humans. However, it is more severe and develops faster in 
monkeys than in humans. Rhesus primates were sacrificed 
after the 5th day of YFV infection and modifications in 
liver functions were detected up to 24h before their death, 
whereas kidney abnormalities were only detected in the 
late stages of the disease (18 to 12 h before death) showing 
that these dysfunctions quickly led to death. Councilman 
bodies (areas of hepatocyte degeneration) and Torres 
bodies (intranuclear eosinophilic granular inclusions) 
have been demonstrated among post-mortem findings. 
Moreover, all kidney sections evidenced tubular necrosis 
and protein deposits that may lead to alterations in the 
kidney hemodynamics, renal azotemia and eventually, 
renal failure14,21,42.
In general, kidney dysfunctions appear between the 
fifth and seventh day of the disease, are characterized by 
the reduction of urinary volume and the urinary loss of 
albumin (a common blood protein). One frequent finding 
is a urinary volume lower than 500 mL/day, even if the 
patient is normovolemic, which may evolve to anuria and 
acute tubular necrosis (ATN). At this stage, there is a high 
rate of mortality. It is a fact that renal ischemia, intravascular 
coagulation, shock and tubular toxicity are induced by 
bilirubin and by direct effects of the virus on kidney 
tissues. If there is no improvement in kidney function, 
renal replacement therapy is indicated (peritoneal dialysis 
or hemodialysis)43,44.
Although it is evident that there is damage in various 
organs such as the liver, kidneys and lymphoid tissue, 
viral antigens are only detected in the liver. According 
to Engelmann et al.42, these observations provide new 
information on the yellow fever pathogenesis, suggesting 
that the kidney and the lymphoid tissue damage may not 
be directly mediated by in situ viral replication, probably 
occurring through soluble mediators that could be 
potentially produced elsewhere42.
The pathophysiology of yellow fever-associated acute 
kidney injury is illustrated in Figure 3.
Unfortunately, there is no available biomarker to 
measure the glomerular filtration rate and detect any kidney 
dysfunction accurately45. 
Even though there are some widely used biomarkers to 
monitor the renal function in chronic diseases such as the 
levels of urea, creatinine, cystatin C, inulin, iothalamate and 
chromium-EDTA45,46, they are not helpful in yellow fever, 
because of the appalling disease severity and progression. 
According to the WHO33, if there is hepato-renal failure, 
up to 50% of the patients will die within 7 to 10 days, and 
those who do not die, may experience a long period of 
recovery from liver and kidney damages15. Consequently, 
these data highlights the importance of more studies on the 
kidney involvement in YF disease, because they are very 
important organs that are indirect targets of the disease, 
with severe consequences. 
About 20 to 50% of death cases involving liver and 
kidney failure due to YFV is a significant high rate that 
should not be ignored. Additionally, renal supportive 
and palliative care procedures have high costs, and can 
compromise the health of patients living in developing 
countries since it will further burden the health budget 
of these countries. That makes this disease even more 
frightening than it could be, if the correct and early 
diagnosis, treatment and preventive measures are not 
adequately applied and are overlooked. 
Treatment
To date, yellow fever treatment consists of intensive 
support by providing hydration, blood transfusions and, 
eventually, renal replacement therapy47. Some studies 
have shown that therapy remains limited to symptomatic 
care in hospitals, and, in the most severe forms of the 
disease, patients must be treated in intensive care units. 
Unfortunately, even though different molecules (polyclonal 
anti-YFV, target viral factors and immunomodulatory 
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compounds) have shown some activity against the virus, 
both in vitro and in vivo, they are not yet available for 
clinical use and have not been approved, as well14,35.
Currently, some new therapeutic options have been 
evaluated, including antiviral medication such as sofosbuvir. 
This drug is a direct antiviral inhibitor of the RNA-directed 
RNA polymerase (NS5B) enzyme of hepatitis C virus, 
which is essential for viral replication. This molecule 
incorporates into the RNA of hepatitis C virus and inhibits 
its replication. This drug is activated in hepatocytes, its 
prodrug is triphosphorylated and predominantly excreted 
by the kidney47,48.
Some mosquito-borne tropical diseases are deemed 
important and have been studied, aiming to apply 
nanotechnology for the production of new drugs to treat 
diseases such as dengue and malaria49. Nanotechnology aids 
in drug delivery, using biological organisms or nanoparticles 
(that can be made of metals such as gold) making drugs 
more disease-specific49. There are no nanodrugs been 
studied for YF yet, since it is a neglected disease, but there 
have been studies on nanopharmaceuticals for malaria, 
which shares the same vector as YF49. 
Prevention
Since YF is a mosquito-borne disease, its eradication can 
be quite challenging, due to the presence of a sylvatic cycle 
of this disease, making it a serious public health problem 
worldwide1,5,14. Having a mosquito as a vector makes YF 
hard to be eradicated, justifying why it is essential to act 
on vector control measures14,37.
In 1927, the yellow fever virus strain Asibi isolated from 
a patient in Ghana was used to formulate the first vaccine. 
The Asibi strain underwent serial passages in chicken 
tissue cultures to be attenuated for human use as a vaccine, 
named the 17D vaccine. There are two types of sub-strains 
obtained from the 17D vaccine, the 17DD and 17D-204. The 
17D strain was first used in Brazil in 1937 for vaccination 
purposes, and since then The Oswald Cruz Foundation has 
produced the yellow fever 17DD (YF-17D) vaccine. To 
produce the 17DD vaccine, a sample of the yellow fever 
virus is inoculated into pathogens-free embryonated chicken 
eggs, as recommended by the WHO14,18.
Since its development in 1930, the YF-17D vaccine 
has been very effective as a preventive action, inducing 
the production of neutralizing antibodies directed against 
the viral envelope protein. Several vaccination strategies 
have been implemented, including YF vaccination in 
children’s routine vaccination calendar, campaigns and 
providing vaccination coverage to travelers visiting yellow 
fever risk zones. In addition to vaccination, vector control 
is imperative and is also classified as a preventive action. 
Nevertheless, the yellow fever virus can also be transmitted 
between humans by the Aedes mosquito, the urban vector, 
Figure 3 - Pathophysiology of yellow fever-associated acute kidney injury. Adapted from Daher and Silva Junior43.
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resulting in urban epidemics. Therefore, yellow fever 
surveillance that includes humans, animals (other primate 
hosts) and vectors deserves special attention in Brazil, 
especially in the Southeast and Midwest regions14,19,20.
Between 2008 and 2009, the transmission of wild 
yellow fever occurred in Sao Paulo and Rio Grande do Sul 
(Southeastern and Southern Brazilian States, respectively). 
These cases of YF were characterized by their occurrence in 
a wide geographic area in which population had no history 
of vaccination. In this period, more than 22 million doses of 
the vaccine were distributed, and the population was alerted 
to the possibility of vaccine-related adverse events. The 
Brazilian health services detected and notified 112 severe 
cases, of which 56 had a causal association with the vaccine. 
Most of the confirmed adverse events were associated 
with the vaccine: 47 cases (84%) had acute neurotropic 
disease and all of them recovered; the other nine cases were 
classified as acute viscerotropic disease and died50.
YF eradication constitutes a global challenge. The 
vaccine plays an important role because it provides long-
term humoral immunity50. Therefore, this long-term 
immunogenicity is very helpful and reduces the morbidity 
and mortality of YF disease, since there is no specific 
treatment for this disease to date50.
According to the WHO, a single dose of the vaccine 
is still very effective and safe, providing long-lasting 
protection against YFV, and there are not many reports on 
YF cases related to vaccination failure14,26,33,51,52. However, 
some adverse effects have been reported, although they 
were all mild reactions that can also occur with other types 
of vaccines14,52.
Another very important action is to emphasize the 
importance of vaccinating travelers going to endemic areas, 
such as Africa and South America countries and encourage 
YF vaccination in these regions, where the mosquito and 
YF are endemic26,52.
According to Shearer et al.26, vaccination coverage 
has increased over the last 50 years due the extensive 
vaccination campaigns, but it is still not enough to eliminate 
YFV53. Moreover, to help some countries in Africa that 
have faced recent YF outbreaks, in June 2017 the WHO 
recommended the use of fractional doses of the YF vaccine, 
if there is a chance of running out of the full vaccine dose54 
for the vaccination coverage of the population. However, 
the recommended fractional dose should be above 1,000 UI, 
and it should be used only to avoid the risk of YF spread, 
providing a one-year protection period53,54. It is only a 
palliative action in cases of low amounts of the vaccine and 
during outbreaks53,54. For this reason, the WHO has been 
stimulating new discoveries using viral genome sequencing 
to improve vaccines15, and some studies have shown that 
polyclonal antibody therapies are very effective against 
many viruses55. 
CONCLUSION
As a viral disease with a huge impact, constituting 
a global public health concern, YF remains poorly 
studied14,33,53. Some reports indicate that genetic variations 
of the disease may occur27. Other aspects that make yellow 
fever a challenging disease are its similarity with other 
hemorrhagic fevers (other Flaviviruses, leptospirosis, 
malaria), the sharing of the same endemics tropical areas, 
and the concomitance of diseases such as the ones caused 
by other arboviruses3,41,56. These aspects can delay the 
diagnosis and management of patients including adequate 
treatment and prevention measures. 
Endemic areas would greatly benefit from more cost-
effective and efficient YF assays to control YF infection4. 
These could prevent outbreaks not only in endemic 
countries, but also in other territories visited by travelers 
coming from endemic areas4. Unfortunately, serological 
diagnostic methods are not very accurate due the low 
levels of circulating immunoglobulins and the high rate 
of cross-reactions between arboviruses in serology. 
Thus, having access to a faster differential diagnosis can 
help to implement the correct treatment and preventive 
measures3,4,27.
Even though yellow fever is a disease that has spread 
along the years throughout tropical countries, it still requires 
more studies in some areas of medical specialization for 
instance, in nephrology, as there is a scarcity of studies on 
the kidney involvement in yellow fever. The kidney is a 
very complex organ and its malfunction leads to YF severe 
forms, in some cases, requiring renal replacement therapy44.
The scarcity of studies on yellow fever-induced 
renal tissue damage can be associated with the non-viral 
replication in kidney tissues42. Moreover, several cases have 
shown a variety of histological findings related to kidney 
damage, such as interstitial nephritis, tubular necrosis, 
interlobular thrombosis in kidney vessels, hemorrhage and 
adrenal gland ischemic necrosis21,30,36,42. 
Although the yellow fever virus cannot be completely 
eradicated due to the existence of a sylvatic cycle, it can be 
prevented if people from endemic areas and travelers to risk 
areas are vaccinated and actions are taken to control the urban 
vector, the Aedes mosquito19,20,53. These simple actions can 
at least prevent the spread of YF disease and new outbreaks 
since the vaccination, to date, is the only available action 
against yellow fever53,54. History shows that every time the 
vaccination was neglected in the past, new cases of YF disease 
resurfaced27 making it necessary to use fractional doses of 
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the vaccine, which unfortunately does not provide long-
term protection53,54. Moreover, molecular biology studies 
using virus-like proteins (VLPs) could be another source 
for vaccine production, which may show fewer side effects, 
since VLPs do not contain viral genetic material56.
Therefore, the spread of yellow fever disease can 
be controlled. However, once the disease is established, 
it is almost impossible to predict how severe it will 
be, especially because its first symptoms can mimic a 
number of respiratory, digestive and urinary non-severe 
infections4,33,36. So far, the treatment for this disease consists 
mainly of providing intensive support33,47,53. The impact 
on important organs such as the liver and the kidneys can 
be fatal33 and will constitute a burden to health care costs. 
For this reason, we suggest that more studies on the kidney 
involvement in yellow fever and the early diagnosis of 
kidney damage should be carried out to minimize the most 
feared outcome, i.e., death, since the currently existing 
diagnostic tools neither help to avoid the severe stages of the 
disease4, nor minimize the economic impact of YF sequelae.
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